

**Virginia's Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting**

*600 East Broad Street – 7th Floor Conference Rooms
Richmond, Virginia 23219*

Thursday, October 19, 2017 - 10:00 a.m.

Welcome and Comments from DMAS' Director

Cynthia B. Jones

Comments from DMAS' Chief Medical Officer

Kate Neuhausen, MD, MPH

Call to Order

Dr. Neuhausen, Chairman

Drug Utilization Review (DUR) Board Update

Rachel Cain, PharmD

Approval of Minutes From April 25, 2017 Meeting

P&T Committee Members

PDL Management

P&T Committee Members

• **PDL Phase II – New Drug Review**

- Differin[®] 0.1% Gel OTC, tazarotene 0.1% cream (generic Tazorac[®]), adapalene-benzoyl peroxide (generic Epiduo[®]) (*Acne Agents, Topical*)
- Testosterone 30mg/1.5ml sol gel pump (generic Axiron[®]) (*Androgenic Agents*)
- Syndros[™] (*Antiemetic/Antivertigo Agents*)
- Eletriptan (generic Relpax[®]) (*Antimigraine Agents, Triptans*)
- Tymlos[™] (*Bone Resorption Suppression and Related Agents*)
- Kevzara[®], Siliq[™] & Tremfya[™] (*Cytokine and CAM Antagonists*)
- Haegarda[®] (*HAE Treatments*)
- Synjardy[®] XR (*Hypoglycemics, SGLT2*)
- Xatmep[™] (*Methotrexate*)
- Arymo[™] ER & MorphaBond[™] ER, buprenorphine (generic Butrans[®]) (*Opioids, Long acting*)
- Oxycodone-acetaminophen (generic Primlev[™]) (*Analgesics, Narcotics Short*)
- Vivitrol[®] (*Opiate Dependence Treatments*) – this is a re-review
- Ellzia[™] Pak Kit (*Steroids, Topical High*)
- Cotempla XR-ODT[™] & Mydayis[™] ER, atomoxetine (generic Strattera[®]) (*Stimulants and Related Agents*)
- Intrarosa[™] (*Vaginal Estrogen Preparations*)

• **PDL Phase I – Annual Review**

Antibiotic-Anti-Infective

- Antibiotics, Vaginal

Antivirals

- Hepatitis C Agents

Blood Modifiers

- Bile Salts
- Phosphate Binders

Cardiac Medications

- Angiotensin Modulators (*ACEs, ARBs, & CCB combination products*)
- Angiotensin Modulators II (*Direct Renin Inhibitors & combination products*)
- Antihypertensives, Sympatholytics
- Beta Blockers (*includes combination products*)
- Calcium Channel Blockers (*includes dihydropyridine and non-dihydropyridine agents*)

Cardiac Medications (continued)

- Lipotropics, Other (*includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agents, Fibrin Acid derivatives, Microsomal Triglyceride Transfer Protein Inhibitors, Niacin derivatives, Oligonucleotide Inhibitors and Omega 3 agents*)
- Lipotropics, Statins
- Pulmonary Arterial Hypertension Agents (*Endothelin-1 agents, PDE-5 Inhibitors; Prostacyclin analogues, Prostacyclin Vasodilators, Soluble Guanylate Cyclase Stimulators*)

Central Nervous System

- Alzheimer's Agents
- Anticonvulsants
- Antidepressants, Other
- Antidepressants, SSRI
- Antipsychotics
- Sedative Hypnotics (*includes other Hypnotics*)

Contraceptives

- Long-Acting Reversible Contraceptives (LARCS) re-review

Dermatologic Agents

- Immunological Atopic Dermatitis
- Steroids, Topical

Endocrine & Metabolic Agents

- Glucocorticoids, Oral
- Growth Hormones
- Hereditary Angioedema (HAE)
- Progestins for Cachexia

Gastrointestinal

- Antiemetic/Antivertigo Agents
- Gastrointestinal (GI) Motility, Chronic
- H. Pylori Treatment
- Histamine-2 Receptor Antagonists (H-2RA)
- Proton Pump Inhibitors
- Ulcerative Colitis (*oral and rectal*)

Genitourinary

- BPH Agents (*includes Alpha Blockers, Androgen Hormone Inhibitors and Phosphodiesterase (PDE) 5 Inhibitors for BPH treatment*)
- Bladder Relaxants

Ophthalmics

- Allergic Conjunctivitis (*includes Ophthalmic Antihistamines & Mast Cell Stabilizers*)
- Antibiotics
- Antibiotic/Steroid Combinations
- Anti-Inflammatory Agents (*includes Ophthalmic NSAIDS & Corticosteroids*)
- Glaucoma Agents (*includes Alpha-2 Adrenergics, Beta-blockers, Carbonic Anhydrase Inhibitors, Prostaglandin Inhibitors*)

Respiratory

- Anti-Allergens, Oral
- Antibiotics, Inhaled
- Antihistamines Minimally Sedating

Respiratory (continued)

- Bronchodilators, Long Acting Beta Adrenergics
- Bronchodilators, Short Acting Beta Adrenergics
- COPD (*includes Anticholinergics, Bronchodilators and Phosphodiesterase 4 (PDE4) Inhibitors*)
- Cough & Cold Agents (*Legend*)
- Epinephrine, Self-Injected
- Glucocorticoids (*includes nebulized solutions, metered dose inhalers and combinations*)
- Intranasal Rhinitis (*includes Antihistamines and Corticosteroids*)
- Leukotriene Modifiers

Confidential Meeting (Pricing Information Discussion)

**P&T Committee, DMAS & MMS Staff
Pursuant to 42 USC §1396r-8**

PDL Recommendations and Vote

P&T Committee Members

Criteria Discussion of Phase II New Drugs*

P&T Committee Members

Criteria Discussion of PDL Phase I Drug Classes*

P&T Committee Members

Next Meeting – April 19, 2018

Dr. Neuhausen, Chairman

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes in Phase I which are scheduled for review at the October meeting and new drugs in PDL Phase II listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase I Annual Reviews – October 2016 to present
- New Drugs in PDL Phase I or II Drug Classes – October 2015 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than **2** minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send requested information to pdlinput@dmass.virginia.gov and dfmoody@magellanhealth.com by **5 p.m. EST on Thursday, September 21, 2017.**

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmass.virginia.gov by **5 p.m. EST Thursday, September 21, 2017.**